clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Isomoto H et al. | Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. | 2005 | Am. J. Gastroenterol. | pmid:16086706 |
Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
Sontag SJ et al. | Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. | 2001 | Am. J. Gastroenterol. | pmid:11374672 |
Kume K et al. | Disappearance of both MALT lymphoma and hyperplastic polyps in the stomach after eradication of Helicobacter pylori. | 2001 | Am. J. Gastroenterol. | pmid:11569719 |
al-Assi MT et al. | Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. | 1994 | Am. J. Gastroenterol. | pmid:8053435 |
Take S et al. | Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. | 2003 | Am. J. Gastroenterol. | pmid:14638340 |
de Bortoli N et al. | Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. | 2007 | Am. J. Gastroenterol. | pmid:17313499 |
Chey WD and Wong BC | American College of Gastroenterology guideline on the management of Helicobacter pylori infection. | 2007 | Am. J. Gastroenterol. | pmid:17608775 |
Savarino V et al. | What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? | 1995 | Am. J. Gastroenterol. | pmid:8540537 |
Froehlich F et al. | Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. | 2001 | Am. J. Gastroenterol. | pmid:11513170 |
Rokkas T et al. | Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. | 2006 | Am. J. Gastroenterol. | pmid:16928256 |
Sánchez-Delgado J et al. | Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. | 2008 | Am. J. Gastroenterol. | pmid:18564109 |
Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
Vakil N | H. pylori treatment: new wine in old bottles? | 2009 | Am. J. Gastroenterol. | pmid:19098845 |
Rokkas T et al. | Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. | 2009 | Am. J. Gastroenterol. | pmid:19098844 |
Lazzaroni M et al. | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. | 1997 | Am. J. Gastroenterol. | pmid:9128316 |
Sapone A et al. | The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. | 2003 | Am. J. Gastroenterol. | pmid:12809821 |
van der Hulst RW et al. | Therapeutic options after failed Helicobacter pylori eradication therapy. | 1996 | Am. J. Gastroenterol. | pmid:8931413 |
Zhou L et al. | A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. | 2014 | Am. J. Gastroenterol. | pmid:24642580 |
Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
Levy M et al. | Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. | 2002 | Am. J. Gastroenterol. | pmid:11866264 |
Christopher K et al. | Clarithromycin use preceding fulminant hepatic failure. | 2002 | Am. J. Gastroenterol. | pmid:11866297 |
Narayani RI et al. | Resolution of collagenous colitis after treatment for Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:11866305 |
Suzuki S et al. | The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. | 2016 | Am. J. Gastroenterol. | pmid:27185079 |
Fennerty MB | Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. | 1998 | Am. J. Gastroenterol. | pmid:9448162 |
Sullivan B et al. | Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:12385435 |
Labenz J and Börsch G | Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7733070 |
Gisbert JP et al. | Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. | 2008 | Am. J. Gastroenterol. | pmid:17764498 |
Forné M et al. | Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. | 1995 | Am. J. Gastroenterol. | pmid:7733075 |
Giannini E et al. | Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. | 2000 | Am. J. Gastroenterol. | pmid:11051345 |
Kim CG et al. | Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. | 2008 | Am. J. Gastroenterol. | pmid:17714557 |
Zullo A et al. | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. | 1997 | Am. J. Gastroenterol. | pmid:9362185 |
Sirimontaporn N et al. | Ten-day sequential therapy of Helicobacter pylori infection in Thailand. | 2010 | Am. J. Gastroenterol. | pmid:20010919 |
Basu PP et al. | A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. | 2011 | Am. J. Gastroenterol. | pmid:21989146 |
Murata H et al. | Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. | 1998 | Am. J. Gastroenterol. | pmid:9820380 |
Laine L et al. | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. | 1998 | Am. J. Gastroenterol. | pmid:9820381 |
Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
Jarbol DE et al. | Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. | 2006 | Am. J. Gastroenterol. | pmid:16771937 |
Bytzer P | Management of the dyspeptic patient: anything goes? | 2006 | Am. J. Gastroenterol. | pmid:16771938 |
Manes G et al. | Eradication of Helicobacter pylori and dosages of esomeprazole. | 2006 | Am. J. Gastroenterol. | pmid:16771971 |
Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
Nakao K et al. | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. | 1997 | Am. J. Gastroenterol. | pmid:9177520 |
Maconi G et al. | Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 | Am. J. Gastroenterol. | pmid:11232676 |
Kadayifçi A et al. | Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease. | 1995 | Am. J. Gastroenterol. | pmid:7872307 |
Veldhuyzen van Zanten S et al. | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. | 2003 | Am. J. Gastroenterol. | pmid:14499772 |